BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $149,017,898 | +82.4% | 5,651,039 | +19.0% | 0.91% | +98.9% |
| Q2 2023 | $81,688,700 | +40.3% | 4,749,343 | +35.2% | 0.46% | +15.4% |
| Q1 2023 | $58,241,544 | +243.8% | 3,512,759 | +58.0% | 0.40% | +401.3% |
| Q4 2022 | $16,941,196 | -15.8% | 2,223,254 | +9.8% | 0.08% | -33.6% |
| Q3 2022 | $20,125,000 | +50.3% | 2,024,640 | +37.3% | 0.12% | -42.5% |
| Q2 2022 | $13,388,000 | +89.5% | 1,474,450 | +111.9% | 0.21% | +140.7% |
| Q1 2022 | $7,064,000 | +2843.3% | 695,915 | +6113.5% | 0.09% | +4200.0% |
| Q3 2019 | $240,000 | -64.4% | 11,200 | -55.2% | 0.00% | -71.4% |
| Q2 2019 | $674,000 | – | 25,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |